SK94099A3 - Cytokine related treatments of disease - Google Patents

Cytokine related treatments of disease Download PDF

Info

Publication number: SK94099A3
Authority: SK; Slovakia
Prior art keywords: compound; disease; imbalance; activity; pharmaceutical composition
Prior art date: 1997-01-17

Application number

SK940-99A

Other languages

English (en)

Slovak (sk)

Inventor

Robert Tam

Guangyi Wang

Devron Averett

Kandasamy Ramasamy

Original Assignee

Icn Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-17

Filing date

1998-01-13

Publication date

2001-06-11

1998-01-13 Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals

2001-06-11 Publication of SK94099A3 publication Critical patent/SK94099A3/sk

Links

201000010099 disease Diseases 0.000 title claims abstract description 36
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 36
102000004127 Cytokines Human genes 0.000 title claims abstract description 26
108090000695 Cytokines Proteins 0.000 title claims abstract description 26
238000011282 treatment Methods 0.000 title abstract description 21
150000001875 compounds Chemical class 0.000 claims abstract description 90
239000002777 nucleoside Substances 0.000 claims abstract description 59
230000004044 response Effects 0.000 claims abstract description 45
239000003814 drug Substances 0.000 claims abstract description 39
230000000694 effects Effects 0.000 claims abstract description 37
150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 25
230000005856 abnormality Effects 0.000 claims abstract description 18
238000013270 controlled release Methods 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 79
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 17
229960000329 ribavirin Drugs 0.000 claims description 17
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 14
206010020751 Hypersensitivity Diseases 0.000 claims description 12
206010028980 Neoplasm Diseases 0.000 claims description 11
208000026935 allergic disease Diseases 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 9
208000015181 infectious disease Diseases 0.000 claims description 9
230000007815 allergy Effects 0.000 claims description 8
210000000056 organ Anatomy 0.000 claims description 7
238000002054 transplantation Methods 0.000 claims description 7
108010050904 Interferons Proteins 0.000 claims description 6
102000014150 Interferons Human genes 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
229940079322 interferon Drugs 0.000 claims description 5
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
230000003612 virological effect Effects 0.000 claims description 5
206010012438 Dermatitis atopic Diseases 0.000 claims description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
239000002246 antineoplastic agent Substances 0.000 claims description 4
239000003443 antiviral agent Substances 0.000 claims description 4
201000008937 atopic dermatitis Diseases 0.000 claims description 4
230000000968 intestinal effect Effects 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
208000009388 Job Syndrome Diseases 0.000 claims description 3
239000013566 allergen Substances 0.000 claims description 3
229940121375 antifungal agent Drugs 0.000 claims description 3
239000003429 antifungal agent Substances 0.000 claims description 3
230000001684 chronic effect Effects 0.000 claims description 3
229940000033 dermatological agent Drugs 0.000 claims description 3
239000003241 dermatological agent Substances 0.000 claims description 3
206010051040 hyper-IgE syndrome Diseases 0.000 claims description 3
239000003018 immunosuppressive agent Substances 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
230000002503 metabolic effect Effects 0.000 claims description 3
210000002966 serum Anatomy 0.000 claims description 3
239000012062 aqueous buffer Substances 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
239000003405 delayed action preparation Substances 0.000 claims 6
208000017667 Chronic Disease Diseases 0.000 claims 2
230000003247 decreasing effect Effects 0.000 claims 2
229940124597 therapeutic agent Drugs 0.000 claims 2
239000002282 antimigraine agent Substances 0.000 claims 1
229940125684 antimigraine agent Drugs 0.000 claims 1
230000033228 biological regulation Effects 0.000 claims 1
231100000673 dose–response relationship Toxicity 0.000 claims 1
238000009472 formulation Methods 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
229940079593 drug Drugs 0.000 abstract description 27
125000003835 nucleoside group Chemical group 0.000 abstract description 17
239000002552 dosage form Substances 0.000 abstract description 2
229910052757 nitrogen Inorganic materials 0.000 description 59
125000000217 alkyl group Chemical group 0.000 description 43
125000003342 alkenyl group Chemical group 0.000 description 24
125000003710 aryl alkyl group Chemical group 0.000 description 24
125000000304 alkynyl group Chemical group 0.000 description 21
229910002091 carbon monoxide Inorganic materials 0.000 description 19
229910052801 chlorine Inorganic materials 0.000 description 18
239000000460 chlorine Substances 0.000 description 18
125000004093 cyano group Chemical group *C#N 0.000 description 18
150000003973 alkyl amines Chemical class 0.000 description 17
229910052794 bromium Inorganic materials 0.000 description 17
229910052731 fluorine Inorganic materials 0.000 description 17
125000000623 heterocyclic group Chemical group 0.000 description 17
229910052740 iodine Inorganic materials 0.000 description 17
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 16
229910052736 halogen Inorganic materials 0.000 description 16
150000002367 halogens Chemical class 0.000 description 16
229910052739 hydrogen Inorganic materials 0.000 description 14
229910052760 oxygen Inorganic materials 0.000 description 13
125000002252 acyl group Chemical group 0.000 description 12
229910052799 carbon Inorganic materials 0.000 description 12
125000005741 alkyl alkenyl group Chemical group 0.000 description 11
125000002877 alkyl aryl group Chemical group 0.000 description 11
125000003118 aryl group Chemical group 0.000 description 11
-1 guanine nucleoside Chemical class 0.000 description 11
229910052717 sulfur Inorganic materials 0.000 description 11
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 10
229920002554 vinyl polymer Polymers 0.000 description 10
XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 9
239000000969 carrier Substances 0.000 description 9
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
235000013902 inosinic acid Nutrition 0.000 description 8
208000023275 Autoimmune disease Diseases 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
206010061217 Infestation Diseases 0.000 description 6
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000000670 limiting effect Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
241000700605 Viruses Species 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
125000006414 CCl Chemical group ClC* 0.000 description 4
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
208000004898 Herpes Labialis Diseases 0.000 description 4
108010074328 Interferon-gamma Proteins 0.000 description 4
206010067152 Oral herpes Diseases 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
230000002902 bimodal effect Effects 0.000 description 4
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
230000009610 hypersensitivity Effects 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
108010036941 Cyclosporins Proteins 0.000 description 3
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
102000008070 Interferon-gamma Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
230000007969 cellular immunity Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229930182912 cyclosporin Natural products 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
125000005017 substituted alkenyl group Chemical group 0.000 description 3
125000000547 substituted alkyl group Chemical group 0.000 description 3
125000004426 substituted alkynyl group Chemical group 0.000 description 3
125000003107 substituted aryl group Chemical group 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
229960003723 tiazofurine Drugs 0.000 description 3
229960002555 zidovudine Drugs 0.000 description 3
MYKLQMNSFPAPLZ-UHFFFAOYSA-N 2,5-dimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC1=CC(=O)C(C)=CC1=O MYKLQMNSFPAPLZ-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
239000002126 C01EB10 - Adenosine Substances 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
241000711557 Hepacivirus Species 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
108010087227 IMP Dehydrogenase Proteins 0.000 description 2
102000006674 IMP dehydrogenase Human genes 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
102000003814 Interleukin-10 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
241000725643 Respiratory syncytial virus Species 0.000 description 2
208000024799 Thyroid disease Diseases 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
229940033350 aclovate Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
229960005305 adenosine Drugs 0.000 description 2
229940009456 adriamycin Drugs 0.000 description 2
230000002411 adverse Effects 0.000 description 2
DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 2
ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 2
229960003099 amcinonide Drugs 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
239000003096 antiparasitic agent Substances 0.000 description 2
229940125687 antiparasitic agent Drugs 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
229960001102 betamethasone dipropionate Drugs 0.000 description 2
CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
239000011280 coal tar Substances 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 2
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical class C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229940063190 flagyl Drugs 0.000 description 2
229940085863 florone Drugs 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000036737 immune function Effects 0.000 description 2
229940073062 imuran Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
229940087973 lomotil Drugs 0.000 description 2
RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
229940063175 lotrimin Drugs 0.000 description 2
229960003439 mebendazole Drugs 0.000 description 2
BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical group Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000011294 monotherapeutic Methods 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
229960001920 niclosamide Drugs 0.000 description 2
RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 2
229960000988 nystatin Drugs 0.000 description 2
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
229940027035 oxsoralen Drugs 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
150000002972 pentoses Chemical class 0.000 description 2
229940097191 phazyme Drugs 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229960003171 plicamycin Drugs 0.000 description 2
230000009467 reduction Effects 0.000 description 2
SDWIOXKHTFOULX-PDNLFSCWSA-N ribavirin monophosphate Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](COP(O)(O)=O)O1 SDWIOXKHTFOULX-PDNLFSCWSA-N 0.000 description 2
150000003870 salicylic acids Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229960004546 thiabendazole Drugs 0.000 description 2
WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 2
235000010296 thiabendazole Nutrition 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
208000021510 thyroid gland disease Diseases 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
229940035306 topicort Drugs 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical class ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 description 1
YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
208000007984 Female Infertility Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
108091058560 IL8 Proteins 0.000 description 1
GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010021928 Infertility female Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
102000003816 Interleukin-13 Human genes 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
102000000585 Interleukin-9 Human genes 0.000 description 1
206010023230 Joint stiffness Diseases 0.000 description 1
125000003376 L-ribosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@@H](O1)CO)* 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
208000007466 Male Infertility Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
210000000447 Th1 cell Anatomy 0.000 description 1
210000004241 Th2 cell Anatomy 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
YWBULOYFCXZCGF-UHFFFAOYSA-N [1,3]thiazolo[4,5-d]pyrimidine Chemical compound C1=NC=C2SC=NC2=N1 YWBULOYFCXZCGF-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000001399 anti-metabolic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007596 consolidation process Methods 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
208000024386 fungal infectious disease Diseases 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
229960004880 tolnaftate Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
229950009795 tucaresol Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Virology (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK940-99A 1997-01-17 1998-01-13 Cytokine related treatments of disease SK94099A3 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US3609497P	1997-01-17	1997-01-17
US4397497P	1997-04-23	1997-04-23
US2858697P	1997-04-23	1997-04-23
US5548797P	1997-08-12	1997-08-12
PCT/US1998/000634 WO1998030223A1 (en)	1997-01-17	1998-01-13	Cytokine related treatments of disease

Publications (1)

Publication Number	Publication Date
SK94099A3 true SK94099A3 (en)	2001-06-11

Family

ID=27487693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK940-99A SK94099A3 (en)	1997-01-17	1998-01-13	Cytokine related treatments of disease

Country Status (15)

Country	Link
EP (1)	EP0998293A4 (de)
JP (3)	JP2002515892A (de)
KR (1)	KR20000070167A (de)
CN (3)	CN1253504A (de)
AU (1)	AU736075B2 (de)
BR (1)	BR9807473A (de)
CA (1)	CA2278158A1 (de)
HU (1)	HUP0001526A3 (de)
IL (1)	IL130497A0 (de)
NO (3)	NO993439L (de)
PL (1)	PL336579A1 (de)
SI (1)	SI9820003A (de)
SK (1)	SK94099A3 (de)
WO (1)	WO1998030223A1 (de)
YU (1)	YU61598A (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6455690B1 (en) *	1996-10-16	2002-09-24	Robert Tam	L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
PY0111577A (es)	2000-05-23	2017-01-02	Idenix Cayman Ltd	Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en)	2000-05-26	2006-08-31	Idenix Cayman Ltd	Methods and compositions for treating flavivirusesand pestiviruses
AU2001292151B2 (en)	2000-08-17	2006-05-04	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en)	2000-08-17	2005-02-22	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en)	2000-08-29	2004-01-20	Tripep Ab	Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en)	2000-08-17	2006-04-04	Tripep Ab	Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
CA2565714C (en)	2004-05-06	2014-12-23	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Methods and compositions for the treatment of uveitis
WO2007104070A1 (en) *	2006-03-14	2007-09-20	Wholesome Biopharm Pty Ltd	Method and composition for treating allergic diseases
WO2009022236A2 (en)	2007-08-16	2009-02-19	Tripep Ab	Immunogen platform
BR112017006264A2 (pt) *	2014-09-26	2017-12-12	Riboscience Llc	derivados de nucleosídeo substituído com 4?-vinila como inibidores de replicação de rna do vírus sincitial respiratório

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4950652A (en) *	1987-03-23	1990-08-21	Hem Research, Inc.	dsRNAs for combination therapy in the treatment of viral diseases
NZ229453A (en) *	1988-06-10	1991-08-27	Univ Minnesota & Southern Rese	A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
ATE221379T1 (de) *	1991-05-01	2002-08-15	Jackson H M Found Military Med	Verfahren zur behandlung infektiöser respiratorischer erkrankungen

1998
- 1998-01-13 SI SI9820003A patent/SI9820003A/sl not_active IP Right Cessation
- 1998-01-13 BR BR9807473A patent/BR9807473A/pt unknown
- 1998-01-13 YU YU61598A patent/YU61598A/sh unknown
- 1998-01-13 SK SK940-99A patent/SK94099A3/sk unknown
- 1998-01-13 IL IL13049798A patent/IL130497A0/xx unknown
- 1998-01-13 CN CN98801801A patent/CN1253504A/zh active Pending
- 1998-01-13 WO PCT/US1998/000634 patent/WO1998030223A1/en not_active Ceased
- 1998-01-13 CA CA002278158A patent/CA2278158A1/en not_active Abandoned
- 1998-01-13 PL PL98336579A patent/PL336579A1/xx unknown
- 1998-01-13 KR KR1019997006393A patent/KR20000070167A/ko not_active Ceased
- 1998-01-13 HU HU0001526A patent/HUP0001526A3/hu unknown
- 1998-01-13 EP EP98903474A patent/EP0998293A4/de not_active Withdrawn
- 1998-01-13 JP JP53124598A patent/JP2002515892A/ja active Pending
- 1998-01-13 AU AU60238/98A patent/AU736075B2/en not_active Ceased
1999
- 1999-07-13 NO NO993439A patent/NO993439L/no not_active Application Discontinuation
2000
- 2000-07-22 CN CN00121912A patent/CN1312254A/zh active Pending
- 2000-08-29 CN CN00126807A patent/CN1289594A/zh active Pending
- 2000-08-31 NO NO20004329A patent/NO20004329D0/no not_active Application Discontinuation
- 2000-08-31 NO NO20004327A patent/NO20004327D0/no unknown
2001
- 2001-05-24 JP JP2001155321A patent/JP2002080490A/ja active Pending
2003
- 2003-04-21 JP JP2003115258A patent/JP2004035546A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
HUP0001526A2 (hu)	2001-05-28
JP2004035546A (ja)	2004-02-05
JP2002080490A (ja)	2002-03-19
NO20004327L (no)	1999-09-13
KR20000070167A (ko)	2000-11-25
AU736075B2 (en)	2001-07-26
CA2278158A1 (en)	1998-07-16
HUP0001526A3 (en)	2002-10-28
AU6023898A (en)	1998-08-03
CN1312254A (zh)	2001-09-12
NO993439D0 (no)	1999-07-13
NO20004327D0 (no)	2000-08-31
YU61598A (sh)	2003-02-28
IL130497A0 (en)	2000-06-01
JP2002515892A (ja)	2002-05-28
SI9820003A (sl)	1999-06-30
WO1998030223A1 (en)	1998-07-16
CN1289594A (zh)	2001-04-04
PL336579A1 (en)	2000-07-03
NO20004329D0 (no)	2000-08-31
EP0998293A4 (de)	2002-07-17
EP0998293A1 (de)	2000-05-10
NO993439L (no)	1999-09-13
NO20004329L (no)	1999-09-13
CN1253504A (zh)	2000-05-17
BR9807473A (pt)	2000-03-21

Publication	Publication Date	Title
US6455508B1 (en)	2002-09-24	Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7166581B1 (en)	2007-01-23	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5968914A (en)	1999-10-19	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
AU727177B2 (en)	2000-12-07	Purine L-nucleosides, analogs and uses thereof
US6423695B1 (en)	2002-07-23	Cytokine related treatments of disease
JP2584947B2 (ja)	1997-02-26	アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤毒性の治療
WO1994026761A1 (en)	1994-11-24	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6455690B1 (en)	2002-09-24	L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
AU736075B2 (en)	2001-07-26	Cytokine related treatments of disease
AU732120B2 (en)	2001-04-12	Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
SK23393A3 (en)	1993-07-07	Uracil reductase inactivators
US7056895B2 (en)	2006-06-06	Tirazole nucleoside analogs and methods for using same
US7776838B1 (en)	2010-08-17	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
EP1380303A1 (de)	2004-01-14	Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
CZ246999A3 (cs)	2000-08-16	Způsob snižující podávanou dávku prvého léku v léčení choroby
HK1057002A (en)	2004-03-12	Cytokine related treatments of disease
HK1052937A1 (en)	2003-10-03	Cytokine related treatments of disease
EP1277759A1 (de)	2003-01-22	Behandlungen von Zytokin-bedingten Krankheiten
MXPA99006418A (es)	2000-04-24	Tratamiento de enfermedad ralacionados concitosina
HRP980477A2 (en)	2000-04-30	Cytokine related treatments of disease
NZ505531A (en)	2001-08-31	7-Propyl-8-oxo-alpha or beta-L-guanine alpha or beta-L-nucleoside
HRP20000421A2 (en)	2000-12-31	Cytokine related treatments of disease
AU743366B2 (en)	2002-01-24	Novel nucleosides
HK1034082A (en)	2001-10-12	Autoimmune nucleosides
HRP20000423A2 (en)	2000-12-31	Novel nucleosides